Stay updated on Pembrolizumab vs Placebo in HCC Adjuvant Therapy Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab vs Placebo in HCC Adjuvant Therapy Clinical Trial page.
Latest updates to the Pembrolizumab vs Placebo in HCC Adjuvant Therapy Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedLocations now include a large set of new sites across the United States (multiple states) and internationally (Argentina, Australia, numerous European and Asian regions), expanding the geographic coverage of the trial.SummaryDifference4%
- Check25 days agoNo Change Detected
- Check40 days agoChange DetectedThe page now shows Revision: v3.3.2 instead of v3.3.1, which is a metadata update. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%
- Check47 days agoChange DetectedA new note explains that Publications are auto-filled from PubMed, and the page revision updated from v3.2.0 to v3.3.1.SummaryDifference0.0%
- Check54 days agoChange DetectedThe location label for site 704 was updated from 'Tainan City, Taiwan, 704' to 'Tainan, Taiwan, 704'. A government funding-status notice text was removed from the page.SummaryDifference0.1%
- Check68 days agoChange DetectedEnrollment is updated to 959 participants and the study's last update is posted on 2025-08-11. Primary completion is 2025-03-20 and estimated study completion is 2025-09-30.SummaryDifference0.1%
- Check97 days agoChange DetectedDifference1%
Stay in the know with updates to Pembrolizumab vs Placebo in HCC Adjuvant Therapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab vs Placebo in HCC Adjuvant Therapy Clinical Trial page.